INTRODUCTION AND OBJECTIVES: Salvage-lymphadenectomy (sLAD) is offered to patients with nodal-only recurrences after radical prostatectomy (RP). However, there is still controversy regarding appropriate patient selection for and oncological benefits from sLAD. Especially with the advent of 68 Ga-PSMA-PET/CT as a highly sensitive targeted imaging tool, the concept of sLAD seems to be a promising approach and evaluation of efficacy is needed.
METHODS: We evaluated perioperative and oncological outcomes of patients with nodal-only recurrences after RP who underwent robotic sLAD at our institution. Recurrence was detected by targeted imaging ( 18 F-Choline-or 68 Ga-PSMA-PET/CT). RESULTS: Data from 26 patients with a median age of 66.5 years [IQR 62; 72] were analyzed with a median time from RP to sLAD of 40.1 months [IQR 14;61.5], median preoperative PSA 2.31 ng/ml [IQR 0.83;5.68]. Imaging of recurrence sites was performed with 18 F-Choline-PET/CT in 11 and 68 Ga-PSMA-PET/CT in 15 patients, the majority of suspicious nodes were located around the iliac vessels (67%). Median operation time was 130.5min [IQR 118; 170] , median blood loss 35ml [IQR 10;100], median hospitalization time 3 days [IQR 3; 4] . The median number of removed nodes was 7 [IQR 4; 14] with a median of 1 [IQR 0;3,5] positive node. While in the first patients only suspicious lymph nodes were removed, an extended bilateral LAD was done in all patients from 2016 on (n¼12). No major complications occurred. Postoperative PSA values were available for 21 patients (10 choline, 11 PSMA), relative PSA-changes from preoperative values are shown in the figure. Complete biochemical response (cBCR, postoperative PSA-nadir <0.2ng/ml) was observed in 6 patients. Median time from sLAD to initiation of systemic treatment was 5 months [IQR 3.3; 13.2] .
CONCLUSIONS: Robotic sLAD is a viable treatment option with low morbidity that can be offered to patients with nodal-only recurrences after RP. Yet, cBCR is only observed in a minority of patients and virtually all patients will eventually have to undergo systemic treatment. Nonetheless, sLAD may at least delay the start of systemic therapy especially with the use of 68 Ga-PSMA-PET/CT, which showed very promising results in our series. 
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INTRODUCTION AND OBJECTIVES:
We sought to compare the safety and effectiveness of two techniques for minimally invasive inguinal hernia (IH) repair, intraperitoneal onlay mesh (IPOM) repair vs. suture repair, in patients undergoing concurrent robotic-assisted laparoscopic radical prostatectomy (RALP).
METHODS: In a single tertiary-care institution study, we retrospectively identified patients who underwent RALP and minimallyinvasive IH repair concurrently from 2010 to 2015. IH were repaired using either an IPOM or a running suture. We assessed the impact of the IH repair technique on perioperative outcomes, 90-day complications, and IH recurrence.
RESULTS: Of 2,239 patients undergoing RALP during the study period, 51 patients (2.3%) underwent concurrent minimally invasive IH repair; 28 underwent IPOM repair, and 23 underwent suture repair. The proportion of patients with previous ipsilateral IH repair was higher in the IPOM group. We found no evidence of a significant difference in age, body mass index (BMI), preoperative physical exam findings, postoperative pain, or overall 90-day complication rates between the two groups. Operative time and length of hospitalization were significantly shorter in the IPOM group. Postoperative complications requiring intervention (Clavien-Dindo III) were more frequent in the suture group (p¼0.03). Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1309
The IH recurrence rate was lower in the IPOM group by a clinically relevant but not statistically significant difference (4% vs. 9%; p¼0.58) CONCLUSIONS: In patients undergoing RALP and IH repair, IPOM repair is feasible, and may be associated with better perioperative outcomes and safety profile than suture repair. The effectiveness of IPOM repair was superior but not significantly. A prospective comparison against the gold-standard technique is warranted.
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LONGITUDINAL HEALTH-RELATED QUALITY OF LIFE AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY Yusuke Kimura*, Masashi Honda, Yetsuya Yumioka, Noriya Yamaguchi, Hideto Iwamoto, Bunya Kawamoto, Toshihiko Masago, Shuichi Morizane, Katsuya Hikita, Atsushi Takenaka, Yonago, Japan INTRODUCTION AND OBJECTIVES: Robot-assisted radical prostatectomy (RARP) has been reported to be associated with less incontinence than a retropubic radical prostatectomy (RRP) and laparoscopic radical prostatectomy (LRP); however, urinary continence continues to occur at a constant rate. There are few reports of urinary incontinence following a RARP to perform a detailed examination of the impact on the patients' postoperative quality of life (QOL). Therefore, in this study, we examined the association between health-related QOL and urinary continence following RARP.
METHODS: From October 2010 to August 2016, 319 patients underwent RARP at our hospital. An SF-8 evaluation was performed for 154 retrospectively selected patients with observable data for 24 months (preoperative, and postoperative 1, 3, 6, 9, 12 , and 24-month evaluations) for our analysis. Evaluation items: physical function (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), mental health (MH), physical component summary (PCS), and mental component summary (MCS) were compared before and after surgery. In addition, "pad free" was defined as no incontinence, and we examined the relationship between the postoperative urinary continence and SF-8 data.
RESULTS: The average age at surgery was 65 (range: 48e76) years, the average preoperative PSA was 9.16 ng/mL (range: 1.17e35.4), and the average prostate volume was 31.6 mL (range: 11e131). We observed a significant reduction at one month post-surgery compared with the preoperative values for all of the scores (all p < 0.0001), and the values recovered to the preoperative status between 3 and 12 months after surgery. The BP, GH, RE, MH and MCS were significantly increased compared with the preoperative values (BP: after nine months; GH: after nine months; RE: after 18 months; MH: after three months; and, MCS: at 12 months). For the group that achieved a pad-free status, the GH, VT, SF, and MH were significantly higher compared to those in the non-achievement group one month after surgery. Moreover, the RF, RP, RE, and MCS were significantly higher in the pad-free achieving group after three months after surgery. Significant differences in BP were not recognized after surgery between the two groups.
CONCLUSIONS: Although all of the scores significantly decreased within one month post-surgery, the values recovered to the preoperative score within 12 months. No urinary continence after surgery appears to be associated with a favorable recovery of patient QOL following RARP. METHODS: Patients diagnosed with prostate cancer were selected from the National Cancer Database between 2010-2013. Patients with biopsy Gleason sum 8 or PSA > 20 and no clinical evidence of metastasis were included for analysis. A Surgical Outcomes for Advanced Prostate cancer (SOAP) score was generated for each patient. Patients received 2 points each for negative surgical margins and sampling of 5 pelvic lymph nodes and 1 point each for no readmission with in 30 days, no mortality within 30 days, and hospital length of stay 2 days. Patients were considered to have a good surgical outcome with a SOAP score 6. Provider volume was e1310 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 
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